Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan

BACKGROUND: Since the precise mechanism for the pathogenesis of systemic lupus erythematosus (SLE) is unknown, no targeted therapies in addition to immunosuppression are available so far. We recently demonstrated that administration of the topoisomerase I (topo I) inhibitor irinotecan at extremely l...

Descripción completa

Detalles Bibliográficos
Autores principales: Keil, Andreas, Hall, Sean R., Körner, Meike, Herrmann, Martin, Schmid, Ralph A., Frese, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075215/
https://www.ncbi.nlm.nih.gov/pubmed/27770825
http://dx.doi.org/10.1186/s13075-016-1144-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075215/
https://www.ncbi.nlm.nih.gov/pubmed/27770825
http://dx.doi.org/10.1186/s13075-016-1144-5

Ejemplares similares